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OpinionNeural networks provide candidate substrates for the
spread of proteinopathies causing neurodegeneration,
and emerging data suggest that macroscopic signatures
of network disintegration differentiate diseases. Howev-
er, how do protein abnormalities produce network
signatures? The answer may lie with ‘molecular nexopa-
thies’: specific, coherent conjunctions of pathogenic pro-
tein and intrinsic network characteristics that define
network signatures of neurodegenerative pathologies.
Key features of the paradigm that we propose here in-
clude differential intrinsic network vulnerability to
propagating protein abnormalities, in part reflecting de-
velopmental structural and functional factors; differential
vulnerability of neural connection types (e.g., clustered
versus distributed connections) to particular pathogenic
proteins; and differential impact of molecular effects (e.g.,
toxic-gain-of-function versus loss-of-function) on gradi-
ents of network damage. The paradigm has implications
for understanding and predicting neurodegenerative dis-
ease biology.
Introduction
Neural networks are a key theme in contemporary neuro-
science [1–3]. Operationally, a neural network can be de-
fined as a complex system comprising nodes and links
represented by neurons and their connections [4]. Neural
networks extend over scales ranging from microscopic (neu-
rons and synapses) to macroscopic (anatomical regions and
fibre tracts), and may be structural (defined by physical
connections; e.g., fibre tracts) or functional (defined by
physiological connections). Neuroimaging techniques, such
as functional MRI (fMRI) and diffusion tensor tractography
[4,5], coupled with methodologies such as graph theory [2,6],
have delineated intrinsic, distributed neural networks
supporting cognitive functions in the healthy brain [7–9].0166-2236/$ – see front matter
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common neurodegenerative syndromes [3–5,7–15], building
on the key insight that neurodegenerative diseases, such as
Alzheimer’s disease (AD) and frontotemporal lobar degen-
eration (FTLD), produce distinctive clinical syndromes with
regular patterns of evolution due to the spread of pathogenic
protein abnormalities via large-scale brain networks.
To date, work in neurodegenerative disease has mainly
focussed on linking clinical phenotypes to network altera-
tions. However, it remains unclear how molecular (protein)
abnormalities translate to network damage and, thus,
clinical phenotypes; and whether pathological substrates
can be predicted reliably from macroscopic network signa-
tures. Recent advances in genetics and histopathology
have enabled the detailed mapping of neurodegenerative
clinico-anatomical phenotypes onto specific proteinopa-
thies, transcending broad categories such as ‘tauopathy’
or ‘ubiquitinopathy’. Histopathological patterns of protein
deposition reflect underlying molecular (biochemical or
conformational) characteristics in a range of neurodegen-
erative diseases, most strikingly in the FTLD spectrum
[16–24]. Although the concept requires further substanti-
ation and qualification, the diffusive intercellular or ‘prion-
like’ spread of pathogenic misfolded proteins holds promise
as a general mechanism for the evolution of the neurode-
generative process in a wide range of diseases [8,9,25–28].
Various candidate mechanisms that might link protein
pathophysiology with intercellular miscommunication
and local circuit disruption have been identified
[3,29,30]. However, the mechanisms that translate local
effects of proteinopathies to specific patterns of large-scale
network disintegration remain largely unknown.
Here, we address this problem. We propose the term
‘molecular nexopathy’ (Latin nectere, tie) to refer to a coher-
ent conjunction of pathogenic protein and intrinsic neural
network characteristics expressed as a macroanatomical
signature of brain network disintegration. We argue that
improved understanding of the molecular mechanisms of
network disintegration will constitute a new paradigm
of neurodegenerative disease. The essential features of
the paradigm that we propose are presented in Box 1
and Figures 1–3. We now consider potential mechanismsTrends in Neurosciences, October 2013, Vol. 36, No. 10 561
Box 1. The molecular nexopathy paradigm: key substrates and constraints
Molecular, microstructural, and functional substrates
Pathogenic proteins, including misfolded aggregates and toxic
oligomers, could promote neural network disintegration by disrupt-
ing synaptic function or maintenance [57], axonal transport or repair
[79], or via ‘downstream’ trophic [58,80] or cell–cell signalling
abnormalities [3,10,29,62,81–85]. Disease effects would exploit in-
trinsic network vulnerabilities: in particular, developmental patterns
of protein expression and structural and functional interactions
across neural circuits [38,39] (Figure 1, main text). Shorter-range or
clustered dendritic and interneuronal connections appear particularly
vulnerable to some tauopathies [48,51], whereas longer-range, more
widely distributed (axonal) projections may be relatively more
vulnerable to other molecular insults (e.g., toxic oligomers derived
from amyloid precursor protein [58] or deficiency of trophic or
protective factors such as GRN [57]). The balance between molecular
net toxic gain-of-function and loss-of-function effects [57,62] might
help to determine the extent to which proteinopathies exert uniform
or graded effects across neural circuits (Figure 1, main text). ‘Soft-
wired’ alterations in synaptic function, in part reflecting pervasive
network activity patterns, might give way to subsequent (irreversible)
‘hard-wired’ structural damage and cell loss.
Disease propagation
Transcellular and, in particular, synaptically mediated diffusion of
misfolded proteins and ‘permissive templating’ of protein misfolding
appear to be general principles of disease evolution across a range of
neurodegenerative proteinopathies [26,86], including prion [85], beta-
amyloid [31–33], tau [87–90], alpha-synuclein [91,92], TDP-43 [71,72],
and superoxide dismutase 1 [27]. Inoculation with beta-amyloid and
tau triggers uptake by cells and ‘templated’ conformational alteration
of normally folded protein to a potentially pathogenic, misfolded
state [26,86]. Trans-synaptic spread of tau-containing tangle pathol-
ogy from entorhinal cortex neurons occurs in transgenic mice that
only express mutant MAPT in those neurons [89,90].
Macroanatomical signatures
Particular structural and functional neuroimaging profiles of net-
work disintegration have specific molecular associations
[7,16,17,20–23,68,69,74,75,93–95] (Figure 2, main text). In the FTLD
spectrum, structural neuroimaging evidence suggests a scheme for
partitioning pathologies according to whether the macroanatomical
brain atrophy profile is localised or distributed, and whether atrophy
is relatively symmetric or strongly asymmetric between the cerebral
hemispheres [18,23] (Figure 2, main text). In the case of AD, early
(even presymptomatic) functional and structural alterations occur
within a specific distributed parieto temporofrontal network mediat-
ing ‘default mode processing’ or stimulus-independent thought in
healthy individuals [4,11] and network disintegration tracks patho-
logical disease staging [11,14,96]. Variant AD phenotypes, such as
posterior cortical atrophy and logopenic progressive aphasia, may
reflect differential involvement of corticocortical projection zones
that together constitute a distributed AD-vulnerable network [15,97],
although the precise pathophysiological roles of the two major
candidate pathogenic proteins (beta-amyloid and phosphorylated
tau) and the factors that modulate the profile of network damage
remain contentious [4,11,15]. Convergence of syndromes as disease
evolves may hold a solution to the problem of phenotypic hetero-
geneity (Figure 3, main text).
Opinion Trends in Neurosciences October 2013, Vol. 36, No. 10whereby molecular dysfunction might be linked to neural
circuit disruption. We then assess the extent to which the
molecular nexopathy paradigm can be reconciled with the
central problems of disease evolution and phenotypic hetero-
geneity, and propose experimental tests of the paradigm in
future work.
How do pathogenic molecules produce specific brain
network disintegration?
Networks show variable intrinsic vulnerability to
proteinopathies
The molecular nexopathy paradigm makes no assumptions
about the instigating event that triggers the neurodegener-
ative process, which might be stochastic but which results in
the creation of a potentially pathogenic molecule. However,
once initiated, the topography of neurodegeneration prefer-
entially targets network elements that are vulnerable to the
instigating molecular species (Figure 1). Emerging evi-
dence, including inoculation experiments in animals [31–
33] (Box 1), implies that a neurodegenerative process may
‘home’ to a brain region (or regions) based on intrinsic
vulnerability to the pathogenic protein. Neurodegeneration
may propagate by ‘prion-like’ seeding or templating of the
protein abnormality (e.g., conformational misfolding) across
neural connections, in addition to physical transfer of insti-
gating pathogenic proteins. The presence of a specific path-
ogenic abnormality that propagates across a network would
distinguish a neurodegenerative molecular nexopathy from
other diseases that disrupt brain networks (for example,
stroke and traumatic brain injury): one important corollary
is that compensatory or homeostatic responses are ultimate-
ly inadequate in neurodegenerative nexopathies.
Regional neural vulnerability to a proteinopathy could
reflect anatomically restricted expression of the culprit562protein by cell populations or additional epigenetic factors
that direct the expression of the protein to particular
brain areas [34–36] or determine neuronal susceptibility
to toxic events [10]. Regional differentiation of protein
expression is a fundamental feature of normal brain
development [37], establishing intrinsic specificities of
connections within neural circuits [38,39] and thereby
in turn directing the function of the circuit. Therefore,
local profiles of protein expression could confer selective
vulnerability or resistance of particular network elements
to particular neurodegenerative diseases, and would also
help drive the functional phenotypic signature of the
disease. For example, differential expression of neuropro-
tective factors has been linked to the relative vulnerabili-
ty of particular neuronal populations in the basal ganglia
in Parkinson’s disease [40], and regional expression of
genes involved in inflammatory signalling may modulate
disease onset with progranulin (GRN) mutations [41]. By
contrast, epigenetic effects during brain development
alter the regulation and expression of amyloid precursor
protein and potentially influence the later development of
AD [42]. Brain areas that are highly neuroplastic, more
specialised, or phylogenetically more recent (for example,
the language system) may be relatively more vulnerable
to proteinopathies [43], whereas primary motor and sen-
sory cortex both show relative resistance. The process of
neurodegeneration might selectively ‘unravel’ the se-
quence of normal ontogeny within the vulnerable network
(for example, by withdrawing essential trophic support,
repair mechanisms, or physiological signalling across
damaged synaptic connections) [29].
Regional specificity might also arise from cellular mor-
phological factors, particularly at synaptic connections:
even if a protein is widely expressed in the brain, its effects
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Figure 1. A taxonomy of molecular nexopathy mechanisms. Here, we model
putative ‘templates’ of neurodegenerative network damage at a given arbitrary
time point following introduction of a pathogenic protein. In each panel, the
stylised local neural circuit comprises nodes (N; e.g., neuronal somas) with links
(e.g., axons or dendrites) that behave as either shorter-range clustered (unfilled
lines) or longer-range distributed (filled lines) connections; the most highly
connected node behaves as a local hub (H), whereas node I is the site of an
instigating insult (wavy arrow) associated with a pathogenic protein. Grey symbols
represent unaffected or minimally affected network elements; pathogenic effects
are coded in red (filled circles representing deleted network elements and half-tone
circles representing dysfunctional network elements) and pathogenic effects are
assumed to be potentially bidirectional across network connections. The
taxonomy shown assumes two basic, interacting dichotomies arising from the
conjunction of pathogenic protein and intrinsic network characteristics: selective
targeting of shorter-range clustered neural connections [e.g., I–N1–N2–H–N3–N4–
N5 (A,B)] versus longer-range distributed neural connections [e.g., I-H-N5-N6,
(C,D)]; and effects that are relatively uniform [no gradient, (A,C)] or strongly graded
[gradient (B,D)] across the network. In each case, the hub H is intrinsically relatively
more vulnerable due to its high connectedness with the rest of the network [60].
Targeting of connection types could reflect subcellular compartmentalisation of
pathogenic proteins and/or local synaptic properties or other morphological
characteristics (e.g., targeting of dendritic versus axonal compartments). Gradients
of effects could be established by intrinsic polarities in network protein expression
and/or the net functional effect of a pathogenic molecular cascade (e.g., uniform
toxic gain-of-function versus graded loss-of-function effects). The model that we
propose requires propagation of disease effects across network elements, but
does not specify the precise nature of those effects: for example, propagation
could occur by direct protein transfer, protein ‘seeding’ or templating in
contiguous elements, or deleterious pathophysiological signalling, all potentially
operating at different stages of disease evolution. The model predicts coherence
between culprit molecule, neural connection types predominantly targeted, and
functional (e.g., cognitive) phenotype as the neurodegenerative process scales to
the level of the whole brain (Figure 2, main text).
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Figure 2. Scaling nexopathies to large-scale brain networks. The inset cartoon
(left) shows a stylised axial view of the cerebral hemispheres in a normal brain.
Circles represent neural network elements and colours code large-scale functional
networks associated with generic clinical syndromes in previous connectivity work
[7]: the anterior temporal lobe semantic network (green); the frontoinsular
‘salience’ network implicated in behavioural variant frontotemporal dementia
(yellow); the dominant hemisphere speech production network implicated in
progressive nonfluent aphasia (magenta); the frontoparietal network associated
with corticobasal syndrome (light blue); and the temporoparietal ‘default mode’
network implicated in Alzheimer’s disease (dark blue). Putative shorter-range
clustered (unfilled black lines) and longer-range distributed (filled black lines)
connections between network elements are shown; connections between major
functional networks are also represented (grey lines). The middle panels show
proposed cross-sectional schemas of network breakdown (red, following Figure 1,
main text), after an instigating insult (wavy arrow) associated with a pathogenic
protein. Alongside each panel, axial and coronal MRI brain sections show
corresponding observed atrophy profiles in patients with representative,
canonical, pathologically confirmed, proteinopathies (CBD, corticobasal
degeneration associated with 4-repeat tau pathology; GRN, mutation in
progranulin gene; MAPT, mutation in microtubule-associated protein tau gene;
TDPC, TDP-43 type C pathology [19], associated with the clinical syndrome of
semantic dementia; the left hemisphere is on the left in all sections). These atrophy
profiles illustrate macroanatomical scaling of the nexopathy templates proposed
in Figure 1 (main text): (A) predominant involvement of clustered (shorter-range)
connections with uniform extension, leading to relatively focal (temporal lobe)
atrophy that is relatively symmetrically distributed between the cerebral
hemispheres; (B) predominant involvement of clustered (shorter-range)
connections with a strong gradient of network damage, leading to relatively
focal (temporal lobe), strongly asymmetric atrophy; (C) predominant involvement
of distributed (longer-range) connections with uniform extension, leading to
distributed, relatively symmetrical atrophy; and (D) predominant involvement of
distributed (longer-range) connections with a gradient of network damage, leading
to distributed, strongly asymmetric atrophy. A particular proteinopathy here
affects network connections with particular characteristics (e.g., clustered versus
distributed synaptic linkages); functional networks will be targeted according to
their specific network characteristics, but the effects of a particular nexopathy will
in general tend to spread between functional networks, while continuing to target
connections with similar properties across these networks. This would account for
empirical variability in the closeness with which proteinopathies map onto
particular functional networks (e.g., the mapping is relatively close for TDPC
pathology with the semantic network, whereas most proteinopathies involve the
salience network). The scheme makes specific predictions about the sequence of
regional involvement with particular proteinopathies (e.g., sequential involvement
of homologous contralateral temporal lobe regions with TDPC pathology) (see also
Figure 3, main text).
Opinion Trends in Neurosciences October 2013, Vol. 36, No. 10may propagate only in particular cell types [44] or across
specific patterns of connections [29]. Animal models have
demonstrated exquisite microanatomical and biochemical
specificity of intercellular connections in key vulnerable
structures (such as hippocampus) [45,46]. Age-related neu-
ronal resprouting may enhance local deposition of amyloid
precursor protein in entorhinal cortex early during the
course of AD [47]. Protein expression and morphological
specificity at receptors and synapses would interact with
subcellular molecular factors. For example, tau isoforms
show distinctive subcellular distributions [48,49]. De-
ranged microtubular transport of abnormal tau facilitates
accumulation of aggregated tau in somatic and dendritic
rather than axonal compartments [50,51], whereas diffus-
ible tau may further focus pathogenic effects of the protein
on local synaptic and glial connections [51]. The role of glial
elements is poorly understood, but may influence local
expression and development of network damage, reflectedmacroscopically in the relative extent of grey matter versus
white matter damage [52].
Proteinopathies are fitted to neural circuits
Central to the molecular nexopathy paradigm is the ‘fit’
between the pathogenic molecule and local neural circuit
(and, ultimately, large-scale network) characteristics
(Figures 1 and 2). Although data on specific local interac-
tions of neural circuits with proteins remain limited, a563
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Figure 3. Temporal evolution of disease and phenotypic heterogeneity. This
schematic illustrates the application of the molecular nexopathy concept to the
problem of phenotypic heterogeneity in neurodegenerative disease, using the
example of corticobasal degeneration. The inset cartoon (left) shows major
functional networks in a stylised normal dominant cerebral hemisphere, colour
coded as in Figure 2 (main text). The panels illustrate evolving network
involvement shortly after onset of the neurodegenerative insult (t0) and at two
arbitrary later time points (t1 and t2). The initial location of the insult (wavy arrow)
determines the clinical presentation (behavioural variant frontotemporal dementia,
bvFTD; progressive nonfluent aphasia, PNFA; or ‘classical’ corticobasal syndrome,
CBS). The core corticobasal functional network (light blue in inset) is involved with
disease evolution in each case; however, variable additional involvement of other
contiguous functional networks (the salience network, speech production network
or default mode network) modulates the phenotype. Each of these phenotypes
arises from a common template of network involvement determined by the type of
neural connection predominantly involved (here, represented as longer-range
distributed intrahemispheric projections); the common nexopathy signature of
corticobasal degeneration is revealed in the temporal profile of disease evolution.
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causing connected regions to develop the same intracellu-
lar protein abnormality or, less directly, by affecting the
function of those connected regions [3]. The coupling be-
tween functional and structural connectivity in neurode-
generative diseases remains poorly defined: however,
initial dysfunction could promote subsequent molecular
alterations and destruction of network elements, as shown
in lesion and tract-tracing studies in humans and nonhu-
man primates [5,6,53]. In more theoretical terms, the
effects of a proteinopathy on a network might be regarded
as a form of ‘information’ flow, where information signifies
a change in network function (in particular, alterations in
synaptic properties) associated with the introduction of the
abnormal protein [3]. The characteristics of information
exchange across artificial neural networks have attracted
considerable interest in computational neurobiology [2,54]:
this theoretical framework might be adapted to the case of
proteinopathies. Pathogenic molecular effects often have
time constants that are much longer than those typically
associated with information flow in neural networks. How-
ever, dynamic downstream alterations in synaptic function
across circuits would occur over much shorter timescales. A
further, potentially related, factor is the role of pervasive
patterns of activity in circuit function and in predisposing
networks to the effects of neurodegenerative disease [55]:
examples include the differential and possibly use-
dependent susceptibility of particular motor pools to
amyotrophic lateral sclerosis (ALS) [27], or the altered564trafficking of amyloid and tau in the isodendritic core
associated with perturbations of the sleep–wake cycle in
AD [56]. Putative behavioural and activity-related factors
are likely to interact with underlying genetic and epige-
netic predisposing factors, and the causal sequence in
general remains to be determined.
An important theoretical motivation for applying the
network information-processing framework to the neurode-
generative proteinopathies is the rich taxonomy of network
activity patterns that follow from relatively simple starting
assumptions when modelling the evolution of artificial neu-
ral networks [54]. In particular, it has been shown in such
artificial networks that patterns of neural activity in local
network elements can, under certain conditions, scale up to
the entire network; that the characteristics of local micro-
circuits strongly influence the activity pattern produced by
the network as a whole; and, furthermore, that these pat-
terns may be highly polarised. All these are network prop-
erties predicted in the case of the neurodegenerative
proteinopathies, for which an ‘activity pattern’ could be
interpreted as the cumulative effect of protein-associated
network damage integrated over time [55].
Relevant network and protein characteristics have yet
to be worked out in detail for neurodegenerative proteino-
pathies. However, it has been shown that brain networks
have ‘small-world’ properties expressed as a high degree of
clustering among network elements and short average
path lengths between clusters [2]. These small-world prop-
erties suggest a basic dichotomy between shorter-range
neural connections within clusters (local neural circuits,
with relatively long neural path length) and relatively
sparse longer-range neural connections (with relatively
short neural path length) between clusters, in line with
highly segregated and hierarchical brain network archi-
tectures observed empirically [6] and with limited evidence
concerning the cellular pathophysiology of certain protei-
nopathies [48,51,57,58] (Box 1). This putative dichotomy
between clustered and distributed network connections
suggests a morphological basis for partitioning neurode-
generative diseases according to whether they produce
relatively localised versus more distributed profiles of
macroscopic brain atrophy [18,20] (Figures 1 and 2). ‘Clus-
tered’ and ‘distributed’ connections could be modelled in
synthetic neural circuits and could be defined in brain
networks using anatomical methods that can measure
effective path lengths between network elements [6]; for
example, dynamic causal modelling. Alternative morpho-
logical dichotomies might also operate: for example, selec-
tive targeting of excitatory versus inhibitory projections
[44].
The degree of macroanatomical asymmetry of network
damage within and between cerebral hemispheres appears
to be a further partitioning characteristic of many neuro-
degenerative diseases (Figure 2), although to demonstrate
interhemispheric asymmetries, it may be necessary to
retain individual hemispheric asymmetry profiles when
pooling data in group neuroimaging studies [18,20–22].
Network asymmetries could be determined, in part, by
configurational features of the host network that might
tend to polarise network activity. Such polarity has been
demonstrated in a computational model of Huntington’s
Opinion Trends in Neurosciences October 2013, Vol. 36, No. 10disease [44]. Asymmetries might be predicted based on
extrapolation from network architectures in the brains of
other species. For example, the nodes of large-scale net-
works in the macaque brain have a highly nonuniform
distribution within the cortex and the connections be-
tween nodes are hierarchically organised [6]. Given that
the human brain shares network homologies with that of
the macaque [53], this architecture would tend to focus
the effects of neurodegenerative disease at particular
vulnerable ‘hub’ regions (for example, in prefrontal cor-
tex and posterior cingulate–precuneus [1,59]). Much
more generally, it has been shown that highly connected
network elements are intrinsically more vulnerable to
extinction following perturbing events in a variety of
hierarchical systems, ranging from ecology to economics
[60]. In the context of neurodegenerative disease, ‘extinc-
tion’ might be equated to destruction of highly connected
network elements after introduction of a pathogenic
protein and susceptibility from connectedness might,
for example, predict disproportionate vulnerability of
dominant hemisphere language hubs in the progressive
aphasias [43] and medial parietal hubs binding the
default mode network in AD [1,4,15,55,59]. If functional
connections between brain regions are defined based on
the strength and direction of spontaneous activity cor-
relations, fMRI data suggest a fundamental dichotomy
between ‘positive’ connections that are dominant within
a cerebral hemisphere versus ‘negative’ connections that
are dominant between hemispheres [61]: negative inter-
hemispheric functional correlations will tend to establish
intrinsically asymmetric interhemispheric interactions
that could be exploited by neurodegenerative pathologies
(Figure 2).
It is unlikely a priori that any set of neuronal or neural
network features would confer vulnerability uniquely to a
single molecular species. However, further specificity in
the profile of network involvement (in particular, whether
strong polarity of damage is expressed across the brain)
may be driven, in part, by functional characteristics of the
pathogenic protein itself.
Directional protein dysfunction drives network
asymmetries
Across the spectrum of potentially pathogenic proteins,
there is a basic distinction between toxic-gain-of-function
(deleterious effects of protein accumulation) and loss-of-
function (impaired physiological, signalling or trophic)
molecular effects [57,62]. The loss of function of a key
protein is likely to lead ultimately to the loss of function
of the affected network element and, therefore, might be
regarded in computational terms as ‘inhibiting’ the affect-
ed element; the net computational effect of a toxic gain of
function is more difficult to predict. Large-scale network
asymmetries (i.e., asymmetric macroscopic atrophy pro-
files) might result from interaction of intrinsic connectivity
structure with a gradient of molecular effects across the
vulnerable network.
We envisage that, within an affected network, an overall
toxic gain of function will spread relatively uniformly,
whereas an overall loss-of-function effect will establish a
gradient of tissue loss due to attenuation of ‘downstream’synaptic inputs. Such polarising network-level effects of
loss-of-function proteinopathies would be in line with a net
‘inhibitory’ action on damaged connections, because selec-
tive inhibition of network elements can generate highly
polarised network structures and self-amplifying network
activity patterns in computational models [54,61,63,64].
Proteinopathic effects would interact with (and may, in
part, be driven by) intrinsic, ontogenetic network gradients
[38,39]. Trophic effects modulate intercellular gradients in
normal morphogenesis and developmental disorders [65]
as well as in computational models [66]. Certain loss-of-
function effects could become self amplifying due to addi-
tional, ‘catastrophic’ mechanisms that might be specific to
particular protein alterations: an example is GRN muta-
tions, which may inhibit neuronal repair processes leading
to accelerated collapse of network architecture [67].
Although it is unlikely that polarised protein effects
operate in pure form in the brain [57,62], for a given
disease process and disease stage, toxic gain-of-function
or loss-of-function effects may dominate at the network
level (Figure 1). Intracellularly, particular pathogenic pro-
teins have complementary loss-of-function and toxic-gain-
of-function effects [62]. However, the overall primary bal-
ance of those effects across a neural network may depend
on specific molecular actions at key network elements (e.g.,
synapses) that act as the final common pathway for net-
work damage. Additional specificity may be conferred by
biochemical characteristics and conformational signatures
of protein subtypes within broad categories, such as tau
and Tar DNA-binding protein 43 (TDP-43) [24,49]. We
currently lack such specific information for most key path-
ogenic proteins in the neurodegenerative spectrum [62].
There is further substantial potential for interactions
among pathogenic proteins (for example, between tau
and beta-amyloid in AD [28]). Protein-specific effects might
modulate intrinsic network connectivity properties, con-
tributing to phenotypic variation associated with particu-
lar proteins within a common network architecture [for
example, the relatively symmetric atrophy profile associ-
ated with microtubule-associated protein tau (MAPT)
mutations versus the strongly asymmetric profile associ-
ated with TDP-43 type C (TDPC) pathology [19] within
anterior temporal lobe networks [18]].
Temporal evolution and the problem of heterogeneity
A critical feature of neurodegenerative molecular nexopa-
thies is likely to be their pattern of evolution in time as well
as spatially within the brain. The rapidity of network
breakdown might depend on the relative proportions of
connection types affected by the pathological process, the
predominant involvement of longer-range connections cor-
responding to rapid spread and involvement of clustered
connections corresponding to slower spread, respectively.
This would fit with available data for certain neurodegen-
erative disorders. For example, patients with MAPT muta-
tions and relatively focal anterior temporal lobe damage
have, on average, slower rates of overall brain atrophy and
survive substantially longer compared with patients with
GRN mutations associated with widespread intrahemi-
spheric damage [68]; interhemispheric asymmetry
increases with advancing disease in association with565
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duce similar local rates of atrophy within key structures
such as the hippocampus [69]. Taken together, such evi-
dence suggests that disease effects are preferentially am-
plified if long intrahemispheric fibre tracts are implicated.
The temporal evolution of atrophy profiles associated
with a particular proteinopathy may reveal a characteris-
tic signature of network involvement that unites appar-
ently disparate phenotypes (Figure 3). For example,
tauopathies in the FTLD spectrum (such as corticobasal
degeneration) may present with a behavioural syndrome
due to frontal lobe involvement, with a language syndrome
due to involvement of peri-Sylvian cortices in the dominant
hemisphere, with a parietal lobe syndrome or with atypical
parkinsonism: the nexopathy paradigm predicts phenotyp-
ic convergence over time due to progressive erosion of
core frontoparietal, frontotemporal, or frontosubcortical
networks implicated in particular tauopathies [18]. There
is substantial evidence for such phenotypic convergence in
the FTLD spectrum [18,70] and related overlap syndromes
such as FTD-ALS [71]; however, precise correlations withBox 2. Testing the paradigm: outstanding questions and future d
Is diffusive protein spread a general mechanism of neurodegenera-
tion?
The strength of evidence for ‘prion-like’ spread, permissive templat-
ing, and direct cell–cell transmission varies among proteinopathies,
and has not been established for some (e.g., fused-in-sarcoma
protein) [98]. Protein spread could occur via mechanisms other than
network pathways (e.g., extracellular diffusion [26,27]). Nonprion
diseases have not been shown to have prion-like spontaneous
infectivity and, typically, evolve more slowly [86].
Hypothesis
Diffusive protein spread is a general mechanism of network disin-
tegration.
Key experiments
Inoculation and tracer studies in animal models [31–33] and the
development of novel molecular model systems [77].
How do protein properties relate to profiles of network degenera-
tion?
Protein properties and expression profiles remain to be related in
detail to cell morphological features, dynamics of cellular transport
mechanisms, and intercellular interactions. For various pathogenic
proteins, the final net ‘direction’ of effects (loss-of-function versus
toxic gain-of-function effects) remains contentious [62]. For several
neurodegenerative diseases, the pathogenic protein species or the
pathogenic form of the protein has not been unambiguously
determined [25].
Hypothesis
Network degeneration arises predictably from interactions of patho-
genic protein properties with specific network morphological and
functional characteristics.
Key experiments
Computational modelling of artificial neural networks with biologi-
cally plausible properties [44]; development of model neural circuits
in vitro [99] and in vivo [38,39]; histomorphometric and immunola-
belling analyses of subcellular protein targets and putative connec-
tion vulnerabilities (e.g., dendritic versus axonal) [48,51]; correlative
phenotypic-histological studies; and cognitive science paradigms to
characterise network activity and architectures [27,30,100].
Are empirical patterns of disease evolution consistent with nexo-
pathy models?
Certain proteinopathies have specific macroanatomical signatures of
network disintegration [4,7,11,13–18,20–23], but disease overlap and
heterogeneity are substantial. The problem of heterogeneity may be
566particular brain networks have yet to be widely estab-
lished. Similarly, variant AD phenotypes have been inter-
preted as modulating a core temporoparietal-prefrontal
‘default mode’ network [15]. Phenotypic convergence
implies that initial stochastic insults anywhere in a vul-
nerable network will lead ultimately to a common signa-
ture of network breakdown, although the precise sequence
of network involvement will tend to reflect the initial locus
of pathology within the network (Figure 3).
This concept of the differential involvement of a core
vulnerable network (with increasingly complete involve-
ment of the network over time) suggests one possible
solution to the apparent paradox of individual phenotypic
variation associated with particular proteinopathies [70].
The clinico-anatomical expression of a given proteinopathy
often varies between individuals as well as between syn-
dromic subgroups [15,27,43]. The molecular nexopathy
paradigm requires that the neuroanatomical profile of dis-
ease evolution is not random, but adheres to a spatiotempo-
ral ‘template’ of network damage: the location of disease
onset within the vulnerable network may vary betweenirections
resolved, in part, by mapping longitudinal profiles of disease
evolution, using neuroimaging tools that can capture convergent
structural and/or functional changes across the brain and over time
[7,8,11]. The molecular nexopathy paradigm makes specific predic-
tions about the sequence of regional evolution with particular
proteinopathies (Figures 2 and 3, main text). fMRI reflects synaptic
function and can assess functional connectivity of networks when
active and at rest [1,7], including potentially compensatory and
homeostatic responses [3,10,73]; in addition, diffusion tensor ima-
ging can assess structural connectivity of white matter pathways that
bind large-scale networks [4,5].
Hypothesis
Macroanatomical spatiotemporal network signatures arise predicta-
bly from underlying molecular lesions.
Key experiments
Longitudinal quantitative tracking of regional tissue damage in
different neurodegenerative diseases in large patient cohorts (in
particular, those with defined molecular lesions) derived from multi-
centre collaborative platforms [101]; connectivity metrics (e.g.,
dynamic causal modelling) to assess relations between network
elements (e.g., putative shorter- versus longer-range connections)
and dynamic, physiologically motivated techniques, such as magne-
toencephalography (MEG) [12]; development of new molecular
ligands (e.g., phosphorylated tau); and practical quantitative metrics
of network function and connectivity [1,2].
What are the implications for disease diagnosis, prognosis, and
treatment?
Besides predicting underlying proteinopathies, improved under-
standing of determinants of network disintegration would enable
the prediction and more accurate tracking of disease evolution.
Identification of specific neural network dysfunction pre-dating the
loss of structural integrity may enable modulation of culprit
molecular deficits. Specific molecular treatments could be directed
at modifying protein mechanisms that sustain network integrity [102]
or bolstering inhibitory processes to counteract excitotoxic effects
[103]. Interventions that reduce local protein concentrations might
ameliorate diffusive protein spread for many diseases.
Hypothesis
Profiles of network disintegration provide biomarkers for tracking
disease evolution and treatment response.
Key experiments
Detailed natural history studies and incorporation of network-level
metrics in clinical trials.
Opinion Trends in Neurosciences October 2013, Vol. 36, No. 10individuals, but progression of the particular disease in
individuals, over time, would tend to recapitulate a charac-
teristic pattern of network involvement. Therefore, to estab-
lish the disease template conclusively will entail detailed
natural history studies: such studies in ALS have exploited
the well-understood and highly regular organisation of the
cerebral motor pools and their connections [27,71,72]. This
example has also underlined the considerable functional
reserve inherent in many brain networks, implying that
‘noisy’ information transfer by surviving elements can sup-
port network functions until a critical stage of network
failure is reached [3,10]. Both neuroimaging and beha-
vioural metrics will be required to capture the ‘prodromal’
phase of early network alterations as well as compensatory
or homeostatic responses [3,11,73].
The effects of a particular proteinopathy need not and
generally will not be restricted to a single vulnerable large-
scale network (Figures 2 and 3). Rather, ‘nexopathy’ inheres
in the type of network connections affected. To the extent
that connections with particular properties are concentrat-
ed in a single functional network, the nexopathy paradigm
would predict that proteinopathies targeting those connec-
tions should principally affect that network: this may ex-
plain the existence of neurodegenerative diseases (such as
those associated with MAPT mutation and TDP-C patholo-
gy) that preferentially target the anterior temporal–inferior
frontal lobe semantic network [7,18,21,69,74,75]. In general,
however, connection types will be represented in more than
one functional network (Figure 2), providing a mechanism
for the spread of proteinopathies between networks, with
further phenotypic variation and potential overlap of clinico-
anatomical profiles among proteinopathies [18,70]. Func-
tional interactions between large-scale brain networks will
also tend to obscure network specificities [76]. Ultimately,
disease spread via secondarily connected systems through-
out the brain implies that network and connection specifici-
ty will be most evident earlier during the evolution of a
particular disease.
As a final important caveat on the differentiation of
nexopathies, it is unlikely that complete specificity will
apply across the entire gamut of pathogenic proteins im-
plicated in neurodegenerative disease. Rather, we envis-
age a taxonomy of predictable profiles of network
disintegration: within the taxonomy, particular profiles
of nexopathy might be common to different pathogenic
proteins to the extent that those proteins share key prop-
erties that promote network damage or dysfunction. Dif-
ferent proteins might, for example, participate in a
common, multicomponent pathogenic cascade (perhaps
best characterised at present for AD [15,57]).
Future directions: testing the molecular nexopathy
paradigm
The molecular nexopathy paradigm requires substantia-
tion drawing on diverse molecular, cellular, and systems
neuroscience (behavioural and neuroimaging) approaches,
including synthetic and in vitro neural circuits, transgenic
and other animal models, and dynamic macroanatomical
techniques [12]. Clinical studies will continue to have a key
role in delineating the sometimes counterintuitive pheno-
types that define brain network disintegration (Figure 2);and phenotyping should be supported by detailed correla-
tive histological studies. If the molecular nexopathy con-
cept can be substantiated, it would hold great potential for
understanding, tracking, and predicting the expression of
neurodegenerative proteinopathies. Indeed, the concept
need not be restricted to proteins: for example, abnormal
cellular signalling linked to carbohydrate moieties could in
principle give rise to ‘sugar nexopathies’ [77]. Several
specific, testable questions follow (Box 2) that collectively
could direct future work. Beyond the principled evaluation
and monitoring of candidate therapies, if mapping network
breakdown is equivalent to mapping the expression of a
molecular lesion, then delineating such a network could be
regarded as a direct ‘in vivo assay’ of the function of the
protein: a concept analogous to that proposed for the
theoretical neural nets of computational neuroscience
[78]. If neural network dysfunction were sufficiently well
specified, this could in turn help identify (or discriminate
between) candidate molecular mechanisms driving the
neurodegenerative process and suggest rational candidate
therapies.
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